Aspire Biopharma Holdings, Inc. Common Stock
Here’s whether Aspire Biopharma Holdings, Inc. Common Stock (ASBP) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-12.39% over 10 days); weak 1-year return of -98.8%; 3-month momentum negative (-87.8%); rising volume on a downtrend (distribution, 2.29x avg). Currently 99.2% off its 52-week high. Score: -6/7.
ASBP is trading below its 200-day MA ($8.54) — a key warning sign the longer-term trend is under pressure. An RSI of 30.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -98.8% compares to +35.1% for SPY (trailed the market by 133.9%). The current 99.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.